Targets › NS5A
8 programs from 8 companies in 9 trials: 5 Phase 4, 2 Phase 2, 2 Phase 3; Infectious disease, Cardiovascular, Oncology; next expected readout Dec 2026.
Open in Phaseline: the race on NS5A, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Oswaldo Cruz Foundation | Epclusa 400Mg-100Mg Tablet HCV NS5A inhibitor and nucleotide NS5B polymerase inhibitor combination | NS5A, NS5B | Phase 4 | Hepatitis C | Dec 2026 |
| Lifespan | Sofosbuvir RNA-directed RNA polymerase inhibitor | NS5B, NS5A | Phase 4 | HEPATITIS C (HCV) | Jan 2027 |
| Catherine Anne Chappell | Sofosbuvir RNA-directed RNA polymerase inhibitor | NS5B, NS5A | Phase 4 | Hepatitis C, Chronic | Aug 2027 |
| Kirby Institute | Pibrentasvir Nonstructural protein 5A inhibitor | NS3, NS5A | Phase 4 | Hepatitis C | Jul 2029 |
| National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Sofosbuvir RNA-directed RNA polymerase inhibitor | NS5B, NS5A | Phase 4 | Diabetes Mellitus | Dec 2032 |
| Atea Pharmaceuticals | Bemnifosbuvir-Ruzasvir (BEM/RZR) HCV NS5B polymerase inhibitor and NS5A inhibitor combination | NS5B, NS5A | Phase 3 | HEPATITIS C VIRUS CHRONIC INFECTION | Dec 2026 |
| Baylor Research Institute | Sofosbuvir RNA-directed RNA polymerase inhibitor | NS5B, NS5A | Phase 2 | Heart Failure | Dec 2026 |
| Amit D Tevar, MD | Sofosbuvir RNA-directed RNA polymerase inhibitor | NS5B, NS5A | Phase 2 | Kidney Transplantation | – |
Hepatitis C (2) HEPATITIS C VIRUS CHRONIC INFECTION (2) HEPATITIS C (HCV) (1) Hepatitis C, Chronic (1) Heart Failure (1) Diabetes Mellitus (1) Kidney Transplantation (1)
small molecule (8)
Lifespan (1) Catherine Anne Chappell (1) Oswaldo Cruz Foundation (1) Kirby Institute (1) Baylor Research Institute (1) National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (1) Atea Pharmaceuticals (1) Amit D Tevar, MD (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.